Integrated genomic characterization of IDH1-mutant glioma malignant progression-Reference-Cited by-同舟云学术

Integrated genomic characterization of IDH1-mutant glioma malignant progression

Published:2015-11-30 Issue:1 Volume:48 Page:59-66
ISSN:1061-4036
Container-title:Nature Genetics
language:en
Short-container-title:Nat Genet

Author:

Bai Hanwen,Harmancı Akdes Serin,Erson-Omay E Zeynep,Li Jie,Coşkun Süleyman,Simon Matthias,Krischek Boris,Özduman Koray,Omay S Bülent,Sorensen Eric A,Turcan Şevin,Bakırcığlu Mehmet,Carrión-Grant Geneive,Murray Phillip B,Clark Victoria E,Ercan-Sencicek A Gulhan,Knight James,Sencar Leman,Altınok Selin,Kaulen Leon D,Gülez Burcu,Timmer Marco,Schramm Johannes,Mishra-Gorur Ketu,Henegariu Octavian,Moliterno Jennifer,Louvi Angeliki,Chan Timothy A,Tannheimer Stacey L,Pamir M Necmettin,Vortmeyer Alexander O,Bilguvar Kaya,Yasuno Katsuhito^ORCID,Günel Murat

Publisher

Springer Science and Business Media LLC

Subject

Genetics

Link

http://www.nature.com/articles/ng.3457.pdf

Reference83 articles.

1. Ostrom, Q.T. et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro-oncol. 16 (suppl. 4), iv1–iv63 (2014).

2. Louis, D.N. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97–109 (2007).

3. Claus, E.B. & Black, P.M. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas. Cancer 106, 1358–1363 (2006).

4. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).

5. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009).

Cited by 259 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Energy metabolism-related GLUD1 contributes to favorable clinical outcomes of IDH-mutant glioma;BMC Neurology;2024-09-13

2. A patient-derived cell model for malignant transformation in IDH-mutant glioma;Acta Neuropathologica Communications;2024-09-10

3. MGMT protein expression is a reliable predictive biomarker for temozolomide‐containing chemotherapy in osteosarcoma;Cancer Science;2024-07-30

4. Epigenetic clocks and gliomas: unveiling the molecular interactions between aging and tumor development;Frontiers in Molecular Biosciences;2024-07-26

5. The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?;Neuro-Oncology;2024-06-24